XML 88 R72.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Details)
$ in Thousands
 12 Months Ended
Jun. 30, 2023
USD ($)
item
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Income Tax Contingency [Line Items]        
(Benefit from) provision for income taxes $ 10,283 $ (15,539) $ 12,318  
Net tax benefit 6,400      
Reconciliation valuation allowance release 9,300      
Reduction in state loss carryforwards 2,340 (5,882) 0  
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount 600      
Valuation Allowance 621 10,390    
Valuation allowance decreased amount 9,800 (5,400)    
Loss on Investment in Subsidiary 0 1,669 0  
Benefit to adjust deferred state tax balances for the acquisition $ 0 $ 1,153 $ 0  
U.S. federal corporate tax rate 21.00% 21.00% 21.00%  
Income tax examination penalties and interest expense $ 700 $ 300 $ 200  
Unrecognized tax benefits, income tax penalties and interest accrued 1,600 900    
Unrecognized tax benefits that would impact effective tax rate 13,100 11,600    
Deferred tax assets, operating loss carryforwards, foreign 17,300 15,700    
Capitalized research and experimental costs 8,075 0    
Unrecognized Tax Benefits 13,128 11,645 $ 9,836 $ 10,473
Deferred tax assets, operating loss carryforwards, state and local $ 190,800 $ 259,900    
Number of operating units local tax incentives | item 3      
U.S. [Member]        
Income Tax Contingency [Line Items]        
Capitalized research and experimental costs amortization period 5 years      
Foreign [Member]        
Income Tax Contingency [Line Items]        
Capitalized research and experimental costs amortization period 15 years